Adline Chem Lab

Who are the top shareholders of the Adline Chem Lab?

The top shareholder of Adline Chem Lab is Hemant Amrish Parikh, with a 25.85% stake. Individual investors own 60.13% of the shares, and there are no mutual funds, foreign institutional investors, or pledged promoter holdings.

The top shareholder of Adline Chem Lab is Hemant Amrish Parikh, who holds 25.85% of the company's shares. Additionally, individual investors collectively own 60.13% of the shares, while there are no mutual funds or foreign institutional investors holding shares in the company. There are also no pledged promoter holdings.

Who are in the management team of Adline Chem Lab?

As of March 2023, the management team of Adline Chem Lab includes Mahendra P Shah (Chairman & Independent Director), Kamlesh J Laskari (Executive Director/Managing Director/Promoter), Ranak K Laskari (Non-Executive Director), and Devarshi D Patel (Independent Non-Executive Director). These individuals are responsible for the company's governance and strategic direction.

As of March 2023, the management team of Adline Chem Lab includes the following individuals:<BR><BR>1. Mahendra P Shah - Chairman & Independent Director<BR>2. Kamlesh J Laskari - Executive Director / Managing Director / Promoter<BR>3. Ranak K Laskari - Non-Executive Director<BR>4. Devarshi D Patel - Independent Non-Executive Director<BR><BR>These members play key roles in the governance and strategic direction of the company.

What does Adline Chem Lab do?

Adline Chem Lab Ltd, a Micro Cap company incorporated in 1988, primarily markets Pharmaceutical and Nutraceutical products. As of March 2025, it reported a net profit of 0 Cr and has a market cap of Rs 9 Cr.

Overview:<BR>Adline Chem Lab Ltd is engaged primarily in the marketing of Pharmaceutical and Nutraceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Adline Chem Lab Ltd was incorporated in 1988 and was formerly known as Kamron Laboratories Limited. The company name was changed on October 13, 2021. The latest quarterly results reported are for March 2025, showing a net profit of 0 Cr.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 9.00<BR>Industry P/E: 35<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.84<BR>Return on Equity: -8.17%<BR>Price to Book: -5.29<BR><BR>Contact Details:<BR>Address: 904 9th Floor, Shapath-I Complex S G Highway Ahmedabad Gujarat : 382721<BR>Tel: 91-02764-286549/286559<BR>Email: info@kamronlabs.com<BR>Website: http://www.kamronlabs.com

Has Adline Chem Lab declared dividend?

No Dividend History Available

Who are the peers of the Adline Chem Lab?

Adline Chem Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ganga Pharma, Fabino Enter, Brawn Biotech, and Shyama Computro. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Ganga Pharma and others exhibit below-average performance, with Divi's Lab having the highest 1-year return at 51.69% and Ganga Pharma the lowest at -46.01%.

Peers: The peers of Adline Chem Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ganga Pharma., Fabino Enter, Brawn Biotech, and Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Divi's Lab., and Dr Reddy's Labs, while Below Average management risk is found at Ganga Pharma., Fabino Enter, Brawn Biotech, and Torrent Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Ganga Pharma., Fabino Enter, and Brawn Biotech. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, and Divi's Lab., while Average capital structure is found at Fabino Enter, and Below Average capital structure is noted for Ganga Pharma., Brawn Biotech, and Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Ganga Pharma. has the lowest at -46.01%, with Adline Chem Lab's own 1-year return at -15.16% being significantly lower than both. Additionally, Ganga Pharma., Fabino Enter, and Brawn Biotech all have negative six-month returns.

Is Adline Chem Lab overvalued or undervalued?

As of April 15, 2024, Adline Chem Lab is considered risky but appears undervalued with a PE ratio of 9.24, significantly lower than peers like Sun Pharma and Cipla, and has recently outperformed the Sensex, suggesting potential recovery and investor interest.

As of 15 April 2024, Adline Chem Lab's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company appears to be undervalued based on its current metrics, with a PE ratio of 9.24, an EV to EBIT of -10.68, and a PEG ratio of 0.00, suggesting that the stock may be trading at a discount relative to its earnings potential.<BR><BR>In comparison to its peers, Adline Chem Lab's valuation stands out as notably lower; for instance, Sun Pharma has a PE ratio of 35.25, while Cipla's is 22.99, both indicating a premium valuation in the industry. Despite the negative capital employed and book value, the company's recent stock performance has outpaced the Sensex, with a 1-month return of 20.81% compared to the Sensex's 3.86%. This performance could signal a potential recovery or investor interest, reinforcing the view that Adline Chem Lab may be undervalued in the current market landscape.

What is the technical trend for Adline Chem Lab?

As of May 14, 2025, Adline Chem Lab's technical trend is mildly bearish, with mixed indicators showing a mildly bullish MACD on the weekly chart, but bearish signals from KST and moving averages.

As of 14 May 2025, the technical trend for Adline Chem Lab has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are mildly bearish on both weekly and monthly time frames. Daily moving averages are also mildly bearish. The KST is bearish on the weekly and monthly charts, while Dow Theory presents a mildly bullish outlook on both time frames. The On-Balance Volume (OBV) is mildly bullish for both weekly and monthly periods. Overall, the current technical stance is mildly bearish, with key indicators like the moving averages and Bollinger Bands contributing to this view.

How big is Adline Chem Lab?

As of 18th July, Adline Chem Lab Ltd has a market capitalization of 9.00 Cr, with recent net sales of 0.00 Cr and a net loss of 0.02 Cr over the last four quarters. Shareholder's funds show a loss of 1.49 Cr against total assets of 0.08 Cr.

As of 18th July, <BR><BR>Market Cap: Adline Chem Lab Ltd has a market capitalization of 9.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 0.00 Cr, while the sum of Net Profit for the same period shows a loss of 0.02 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025. Shareholder's Funds are recorded at a loss of 1.49 Cr, and Total Assets amount to 0.08 Cr.

Are Adline Chem Lab latest results good or bad?

Adline Chem Lab's latest results show stability in net sales but improvements in profitability, with a Profit After Tax of Rs 0.16 crore, up from a loss last year. Overall, the results lean towards positive, indicating a recovery from previous losses.

Adline Chem Lab's latest financial results present a mixed picture. While the overall performance has remained flat with no significant changes in net sales, there are positive signs in profitability metrics. The company has reported a Profit After Tax (PAT) of Rs 0.16 crore for the latest six-month period, a notable recovery from a loss of Rs 0.26 crore in the previous year. <BR><BR>Additionally, the Operating Profit Before Depreciation, Interest, and Taxes (PBDIT) has reached its highest level in the last five quarters, although it remains slightly negative at Rs -0.03 crore. The Profit Before Tax (PBT) has also improved, reaching Rs -0.06 crore, which is the best performance in this area over the same period.<BR><BR>Overall, while the flat sales growth indicates stability, the improvements in profitability suggest that Adline Chem Lab is on a positive trajectory, making the latest results lean more towards the good side, especially in terms of recovery from previous losses.

When is the next results date for Adline Chem Lab?

The next results date for Adline Chem Lab is 12 November 2025.

The next results date for Adline Chem Lab is scheduled for 12 November 2025.

How has been the historical performance of Adline Chem Lab?

Adline Chem Lab has experienced a significant decline in financial performance, with net sales and total operating income dropping to zero from March 2023 to March 2025, following a peak of 6.33 Cr in March 2021. The company has reported negative operating profit and shareholder's funds, indicating severe operational challenges and a complete halt in revenue generation.

Answer:<BR>The historical performance of Adline Chem Lab shows a significant decline in financial metrics over the years, particularly from March 2022 onwards.<BR><BR>Breakdown:<BR>Adline Chem Lab's net sales have dropped to zero from March 2023 to March 2025, following a peak of 6.33 Cr in March 2021. Total operating income mirrored this trend, falling to zero in the same period after reaching 6.33 Cr in March 2021. The company's total expenditure, excluding depreciation, also decreased significantly, from 6.56 Cr in March 2021 to 0.32 Cr in March 2025. Operating profit (PBDIT) has been negative since March 2022, with a loss of -0.07 Cr reported in March 2025. Profit before tax and profit after tax have similarly shown negative values, with the latter reaching -0.13 Cr in March 2025. The company's shareholder's funds have turned negative, standing at -1.49 Cr in March 2025, while total liabilities have decreased to 0.08 Cr. Cash flow from operating activities has remained at zero since March 2022, indicating a complete halt in operational cash generation. Overall, the financial trajectory of Adline Chem Lab reflects severe operational challenges and a lack of revenue generation in recent years.

Should I buy, sell or hold Adline Chem Lab?

Why is Adline Chem Lab Ltd falling/rising?

As of 18-Jan, Adline Chem Lab Ltd's stock price is rising at 11.18, reflecting a 4.98% increase due to strong short-term performance. However, concerns about negative book value, weak long-term growth, high debt, and declining investor confidence may pose risks to future performance.

As of 18-Jan, Adline Chem Lab Ltd's stock price is rising, currently at 11.18, reflecting a change of 0.53 or 4.98% increase. This rise can be attributed to its strong short-term performance, as the stock has outperformed the sector by 6.09% today. Additionally, over the past week, the stock has shown a significant increase of 10.15%, while the benchmark Sensex has remained nearly flat at -0.01%. <BR><BR>However, despite the recent uptick, there are underlying concerns that could affect future performance. The stock has a negative book value and has demonstrated weak long-term growth, with net sales and operating profit stagnating over the last five years. Furthermore, the company has a high debt-to-equity ratio and has reported a negative EBITDA, indicating financial instability. <BR><BR>Investor participation has also been declining, as evidenced by a 78.26% drop in delivery volume on January 13 compared to the five-day average. Promoter confidence appears to be waning, with a 3.76% reduction in their stake over the previous quarter. This trend of decreasing promoter stake could signal a lack of confidence in the company's future prospects.<BR><BR>In summary, while the stock is currently rising due to short-term performance metrics, significant long-term challenges and declining investor confidence could pose risks moving forward.

Which are the latest news on Adline Chem Lab?